Brooks L. Rademacher

CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel‐induced cytotoxicity

David Z. Qian, Brooks L. Rademacher, Janét Pittsenbarger et al. · The Prostate · 2009 · 111 citations · Full text

A strategy for the integration of QTL, gene expression, and sequence analyses

Robert Hitzemann, Barry Malmanger, Cheryl Reed et al. · Mammalian Genome · 2003 · 74 citations

Bioinformatics, Plant Gene Expression, Gene Recognition +11

Histologic Changes Associated With Neoadjuvant Chemotherapy Are Predictive of Nodal Metastases in Patients With High-Risk Prostate Cancer

Catherine O′Brien, Lawrence D. True, Celestia S. Higano et al. · American Journal of Clinical Pathology · 2010 · 70 citations · Full text

Urology, Surgical Oncology, Nodal Metastases +13

C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results

R. Prins, Brooks L. Rademacher, Solange Mongoue‐Tchokote et al. · Urologic Oncology Seminars and Original Investigations · 2010 · 64 citations

Prognostic Biomarkers, Urology, Confirmatory Results +8

The Iroquois Homeobox Gene 5 Is Regulated by 1,25-Dihydroxyvitamin D3 in Human Prostate Cancer and Regulates Apoptosis and the Cell Cycle in LNCaP Prostate Cancer Cells

Anne Myrthue, Brooks L. Rademacher, Janét Pittsenbarger et al. · Clinical Cancer Research · 2008 · 62 citations

Chemoprevention Strategy, Vitamin D3, 1,25-Dihydroxyvitamin D3 +14